Aditya Kohli, Ph.D.

Aditya is a Partner with Frazier Life Sciences, where he focuses on company creation.

Since joining Frazier in 2016, he has co-founded six companies including HilleVax (NASDAQ: HLVX), Phathom Pharmaceuticals (NASDAQ: PHAT), and Scout Bio (Acquired by Ceva). He served as Chief Business Officer of Phathom Pharmaceuticals from 2019-2021 and Chief Operating Officer of HilleVax from 2020 to 2024. He previously served on the boards of HilleVax and Scout Bio.

Prior to Frazier, Aditya was an Engagement Manager with McKinsey & Company, where he served biopharmaceutical companies on business development, research and development, and marketing/sales strategy. He received his Ph.D. from the UC Berkeley and UC San Francisco joint graduate program in bioengineering and holds B.S. and M.Eng. degrees in biological engineering from MIT.